提高既往妊娠期糖尿病女性产后糖尿病筛查参与率的干预措施:系统综述与贝叶斯网络荟萃分析
本系统综述与贝叶斯网络荟萃分析纳入40项研究、共17123名女性,评估提高妊娠期糖尿病女性产后糖尿病筛查参与率的干预措施。基于随机对照试验的网络荟萃分析显示,产前小组教育概率排名最高(OR 10,95%CI 1.6-77.0),其次为一对一教育联合书面材料或咨询(OR 6.9,95%CI 3.6-16.0)。非随机研究显示灵活筛查方式影响最大(OR 3.9,95%CI 1.8-10.0)。
要点
- 产前小组教育在随机对照试验网络荟萃分析中最可能有效(OR 10,95%CI 1.6-77.0)。
- 非随机研究中灵活筛查方式对筛查参与率影响最大(OR 3.9,95%CI 1.8-10.0)。
- 多模式干预和提醒措施若更具理论依据并更好融入医疗体系仍可能重要。
核心结论
- 证据提示产前小组教育和更灵活的筛查方式与产后糖尿病筛查参与率最大幅度提高相关。
- 多模式干预和提醒措施若更具理论依据并更好融入医疗体系仍可能重要。
研究设计与样本
- 系统综述与贝叶斯网络荟萃分析,检索Web of Science、Embase、Cochrane Library、CINAHL和PubMed自建库至2023年3月20日。
- 纳入40项研究,汇总17123名女性数据;随机对照试验11项(美国3项、非美国8项),非随机研究29项(美国13项、非美国16项)。
- 采用Joanna Briggs Institute清单进行质量评价。
主要发现
- 报告筛查结局的14项研究中,11项检出早期2型糖尿病,范围为2.0%至23.0%。
- 随机对照试验网络荟萃分析:产前小组教育概率最高(OR 10,95%CI 1.6-77.0,基于1项美国研究),其次为一对一教育联合书面材料或咨询(OR 6.9,95%CI 3.6-16.0)。
- 非随机研究结果:灵活筛查方式影响最大(OR 3.9,95%CI 1.8-10.0,基于2项美国研究),其次为教育干预联合产前患者教育和书面材料(OR 3.4,95%CI 1.9-6.3,基于1项美国研究和2项非美国研究)及产前小组(OR 3.3,95%CI 1.7-6.7)。
关键数值与推荐
- 纳入标准为涉及提高妊娠期糖尿病女性产后糖尿病筛查参与率干预措施的定量研究。
- 干预类型包括提醒(如信件、电子邮件、电话留言)、教育干预、筛查方法与实施、政策变化、产前小组和多模式干预。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to summarize the current interventions aimed at improving postpartum diabetes screening attendance and to compare their effectiveness. DATA SOURCES: Literature searches were conducted in the Web of Science, Embase, Cochrane Library, CINAHL, and PubMed from inception to March 20, 2023. STUDY ELIGIBILITY CRITERIA: Quantitative studies involving an intervention to increase postpartum diabetes screening attendance among women with gestational diabetes mellitus were included. METHODS: The Joanna Briggs Institute checklists were used for the quality appraisal of the included studies. A Bayesian network meta-analysis was performed to synthesize the comparative effectiveness of the relevant interventions aimed at improving postpartum diabetes screening rates. RESULTS: A total of 40 studies were included in this review with pooled data from 17,123 women. Studies included randomized controlled trials (n=11, including 3 US-based studies and 8 non-US-based studies) and nonrandomised studies (n=29, including 13 US-based studies and 16 non-US-based studies). Of the 14 studies that reported screening outcomes, 11 detected early type 2 diabetes at a rate ranging from 2.0% to 23.0%. The types of interventions identified included reminders (eg, postal letters, emails, and phone messages), educational interventions, screening methods and delivery, policy changes, antenatal groups, and multimodal interventions. Based on the network meta-analysis from randomized controlled trials, antenatal group intervention, which refers to antenatal patient education delivered in groups (1 US-based study), had the highest probability to be the most effective intervention (odds ratio, 10; 95% confidence interval, 1.6-77.0), followed by one-to-one educational intervention with written educational materials or counselling (odds ratio, 6.9; 95% confidence interval, 3.6-16.0). The results from nonrandomized studies indicated that flexible screening methods and delivery (2 US-based studies) had the greatest impact on screening uptake (odds ratio, 3.9; 95% confidence interval, 1.8-10.0), followed by educational interventions (1 US-based study and 2 non-US-based studies) with antenatal patient education and written educational materials (odds ratio, 3.4; 95% confidence interval, 1.9-6.3) and antenatal groups (odds ratio, 3.3; 95% confidence interval, 1.7-6.7). CONCLUSION: The presented evidence suggests that antenatal patient education delivered in groups and offering more flexible screening methods were associated with the greatest increase in attendance. The multimodal interventions and reminders could still be important if they were more theoretically grounded and were more integrated into the healthcare system.
引用
- Huang J, Forde R, Parsons J, et al. Interventions to increase the uptake of postpartum diabetes screening among women with previous gestational diabetes: a systematic review and Bayesian network meta-analysis. Am J Obstet Gynecol MFM. 2023. PMID: 37619781. doi:10.1016/j.ajogmf.2023.101137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。